Top

Trends in allogeneic stem cell transplantation (HSCT) over two decades in patients with secondary acute myelogenous leukemia (sAML) being transplanted from sibling (MSD) or unrelated donors (UD). A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Acute Leukemia Working Party (ALWP)
Study type:
Retrospective Studies
Study number:
8421186
Type of Stem Cell Treatment:
Allogeneic
Diseases:
Acute Myeloid Leukaemia (AML)
Short title:
Trends in allo for sec AML
Primary objective:
This study is a retrospective registry-based analysis to study trends in HSCT outcome over two decades (2011-2020 vs 2000-2010) in patients with sAML undergoing transplantation from sibling or unrelated donors.
Key inclusion criteria:
• sAML including therapy related AML (tAML)
• adults, age ≥ 18 years
• Transplant dates 2011-2020 vs 2000-2010
• HLA matched sibling or 9-10/10 unrelated donors
• PBSC or bone-marrow as the stem cell source
• CR1
• Myeloablative (MAC) or Reduced- intensity conditioning
• All cytogenetics risk
Country:
 
Principal investigator:
Arnon Nagler